Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: October 2009
-
October 14, 2009 – Developments in Pharmaceutical and Biotech Patent Law (Practising Law Institute) – San Francisco, CA October 15-16, 2009 – Patent Litigation 2009 (Practising Law Institute) – Chicago, IL October 20-21, 2009 – 17th Forum on Biotech Patenting (C5) – London, United Kingdom October 22-23, 2009 – Pharmaceutical Congress on Paragraph IV Disputes***…
-
By Donald Zuhn — In August, we noted negative economic indicators for the biotech/pharma industry were finally giving way to more positive signs (see "Is Biotech/Pharma Beginning to Bounce Back?"). Among the positive signs was the return of the biotech/pharma initial public offering (IPO), with Cumberland Pharmaceuticals becoming the first U.S. drug company to…
-
By Donald Zuhn –– Earlier today, the U.S. Patent and Trademark Office issued a press release announcing that Director David Kappos had "signed a new Final Rule rescinding highly controversial regulations, proposed by the previous administration, that patent applicants felt unduly restricted their capacity to protect intellectual property" (see "'New Rules' Officially Rescinded"). Not…
-
By Kevin E. Noonan — The infamous "claims and continuation" rules promulgated over the vocal protests of patent applicants and the patent bar by the Dudas administration of the U.S. Patent and Trademark Office have been officially rescinded by Director David Kappos. In a press release expected to be issued shortly, the Office will…
-
By Suresh Pillai — Federal Court Approves Eloxatin® Settlement Agreement The U.S. District Court for the District of New Jersey has signed off on Sanofi-Aventis' settlement agreement with Sun Pharmaceutical Industries Ltd. despite the fact that Sanofi failed to exchange all relevant signature pages. The agreement ends the litigation over a generic version of…
-
By Kevin E. Noonan — Commerce Secretary Gary Locke (at right) has written a letter to the Senate Judiciary Committee giving qualified support to S. 515, the patent "reform" bill voted out of committee months ago but languishing in the wake of more pressing health care reform legislation. Unfortunately, upon close reading, the Secretary's…
-
By Donald Zuhn –- On Thursday, the U.S. Patent and Trademark Office announced that it was expanding the First Action Interview pilot program to encompass additional technology areas effective October 1, 2009. The pilot program, which began on April 28, 2008, allows applicants of certain applications to interview their cases prior to the issuance…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Genzyme Corp. v. Endo Pharmaceuticals Inc.1:09-cv-02589; filed October 1, 2009 in the District Court of Maryland Infringement of U.S. Patent No. 5,667,775…
-
October 5-6, 2009 – Patent Litigation 2009 (Practising Law Institute) – McLean, VA October 7-8, 2009 – Maximizing Pharmaceutical Patent Lifecycles*** (American Conference Institute) – New York, NY October 14, 2009 – Developments in Pharmaceutical and Biotech Patent Law (Practising Law Institute) – San Francisco, CA October 15-16, 2009 – Patent Litigation 2009 (Practising Law…
-
By Donald Zuhn — On Tuesday, ten Governors sent a letter to Congressional leaders expressing their support for Congress' efforts to pass legislation that would create a follow-on biologics regulatory pathway. Noting that "[t]his critically important issue has a direct economic impact on our states, our nation's public health, our economic success, and our…
Patent Docs 